Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, but adjusted profits excluding exceptions ...

Choice Broking maintained an ‘ADD’ rating and a target price of Rs 1,825 on Sun Pharma. At the prevailing price, the target ...

Sun Pharmaceutical's shares fell 5.7% to ₹1,608.30 after a 20% drop in net profit to ₹2,278 crore for Q1 FY26. Despite this, ...

India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

Mumbai: Drugmaker Sun Pharmaceutical Industries reported a 20 percent year-on-year decline in consolidated net profit to Rs 2 ...

Sun Pharma stock fell as much as 5.78% during trade so far to Rs 1,608 apiece on the NSE. It was trading 3.65% lower at Rs ...

Healthy double-digit growth in its India business and innovative medicines pipeline boosted its revenue and Ebitda margins ...

Sun Pharmaceutical, India's largest drug maker, is not planning to expand its manufacturing base in the US, citing sufficient ...

LEQSELVI (deuruxolitinib) 8 mg tablets is an oral selective inhibitor of Janus kinases JAK1 and JAK2 approved for the treatment of adult patients with severe alopecia areata.

LEQSELVI demonstrated rapid results in clinical trials with one third of patients regaining almost all of their hair by Week 24. Some patients (3%) achieved 80% or more scalp coverage as fast as 8 ...

The approval of Leqselvi for adults with severe alopecia areata (at least 50% scalp hair loss) was based on positive results from two phase 3 clinical trials: THRIVE-AA1 (ClinicalTrials.gov ...

Sun Pharmaceutical Industries reported a 20% decline in net profit for Q1 FY26, standing at ₹2,279 crore. The fall is ...